On July 15, Akeso rose 3.86% in regular trading, trading at 100.5 HKD/share, with turnover of HK$173 million. The gain was driven by the company's announcement of a collaboration with Memorial Sloan Kettering Cancer Center (MSKCC) to advance a Phase II clinical trial of cadonilimab in the United States.

On July 14, Akeso announced the partnership with MSKCC to evaluate its globally first-in-class PD-1/CTLA-4 bispecific antibody cadonilimab in combination therapy for perioperative treatment of locally advanced, resectable HER2-negative gastric or gastroesophageal junction adenocarcinoma. The study has already enrolled patients in the US and is led by internationally renowned gastrointestinal oncologist Dr. Yelena Janjigian, who previously spearheaded landmark trials including CheckMate 649 and MATTERHORN. The Phase II data will provide clinical evidence supporting a subsequent international multi-center Phase III registrational study.

Cadonilimab is the world's first approved tumor immunotherapy bispecific antibody, currently with over 13 registrational/Phase III studies underway globally. Multiple brokerages maintain Buy ratings on Akeso, citing its leading bispecific antibody platform and robust pipeline.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)